ImCheck Therapeutics

Executive Summary

ImCheck Therapeutics is a private French biotechnology company pioneering immunomodulation therapies targeting the butyrophilin (BTN) and BTN-like superfamily of immune checkpoints. Founded in 2015 and headquartered in Marseille, the company leverages its unique expertise to develop next-generation antibody therapeutics for cancer, infectious diseases, and autoimmune disorders. ImCheck's lead program, ICT-01, is a first-in-class anti-BTN3A antibody designed to activate Vγ9Vδ2 T cells, offering a novel mechanism to engage the immune system against tumors. The company has also built a pipeline of candidates targeting other BTN family members for additional indications. Despite being in early stages, ImCheck's platform has potential to address significant unmet needs, though clinical validation remains limited.

Upcoming Catalysts (preview)

• Q1 2027Phase 1/2a clinical data readout for ICT-01 in solid tumors40% success
• Q4 2026IND filing or European clearance for second-generation BTN-targeted antibody50% success
• Q2 2027Partnering deal or grant for autoimmune/infectious disease program30% success